FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting DNA Replication Stress in treatment-resistant cancers.

FoRx is developing first- and best-in-class compounds for cancer treatment by focusing on drugging key molecular targets involved in DNA replication stress, a new approach towards the development of targeted anticancer drugs.

Our team consists of executive leadership, scientists and advisors with extensive experience in cancer biology, medicinal chemistry, small molecule drug discovery and clinical development in oncology indications – including in-depth expertise in DNA replication stress and associated DNA Damage Response pathways.

FoRx is located in Basel, Switzerland, a world-leading hub of the biotech and pharmaceutical industry.